Title of Program: What has Cochrane Neonatal Done For Babies? Speakers/Moderators: Roger F. Soll, MD Planning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll, MD Date: September 2017 Learning Objectives: Participants will be presented with evidence from clinical trials and systematic reviews and will be able to evaluate and translate the evidence in the field of neonatology to better serve their practices. Specifically, evidence from a variety of systematic reviews in Neonatal-Perinatal Medicine will be reviewed to evaluate their impact on practice and guidelines. DISCLOSURE: Is there anything to disclose? No financial interests to disclose COMMERCIAL SUPPORT ORGANIZATIONS (if applicable): No Commercial Support What has Cochrane Done for Babies? Roger F. Soll, MD H. Wallace Professor of Neonatology University of Vermont College of Medicine Coordinating Editor, Cochrane Neonatal President, Vermont Oxford Network This activity has been planned and implemented by The Robert Larner College of Medicine at The University of Vermont and Cochrane Neonatal is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team. The University of Vermont designates this web seminar for a maximum of 1 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Cochrane Neonatal Web Seminar September 29 th 2017 Trusted evidence. Informed decisions. Better health. The Basics Follow slides on the Internet Listen on your phone or speakerphone Chat feature - questions anytime Your phone will be muted during talks Questioner unmuted during Q&A Use the raised hand icon to queue up for questions Cochrane Preparing, maintaining and promoting the accessibility of systematic reviews of the effects of health care interventions Cochrane Neonatal Prepares and disseminates evidence-based reviews of the effects of therapies in the field of neonatal medicine Editorial Team Editorial Team Michael Bracken Yale University Jeffrey Horbar Bill McGuire University of Vermont Hull York Medical School Gautham Suresh Baylor University Roger F. Soll Coordinating Editor Colleen Ovelman Managing Editor Jennifer Spano Information Specialist 1
Editorial Team Support Danielle Ehret, MD, MPH University of Vermont Disclosure Roger F. Soll is the Coordinating Editor of Cochrane Neonatal previously supported by a contract from the NICHD and President of Vermont Oxford Network Why These Webinars? To develop an understanding of the evidence supplied by systematic reviews in neonatal perinatal medicine (as well as other large well conducted trials) and discuss how this evidence might influence your practice. COCHRANE COLLABORATION Cochrane Collaborative Groups Over 50 Collaborative Review Groups Most address specific disease entities/health problems The Cochrane Neonatal Review Group; one of the rare groups that address the needs of a population What do we do? COCHRANE NEONATAL - prepare and disseminate evidence-based reviews of the effects of therapies in the field of neonatal medicine. - reviews follow a standard method: a well formulated question a comprehensive search for eligible trials critical appraisal of trial quality quantitative synthesis of the results using meta-analysis - reviews are regularly updated as new trials are published. 2
SYSTEMATIC OVERVIEW META-ANALYSIS - Applies specific research strategies to identify, appraise, and synthesize data from all relevant clinical studies What s the use of meta-analysis? Quantitative systematic reviews include meta-analyses: - statistical methods to combine the results of similar randomized controlled trials to produce a typical estimate of the effect size increase statistical power increase precision of estimate explore differences between study results create structure for incorporating new evidence COCHRANE NEONATAL These Cochrane systematic reviews are published in the Cochrane Database of Systematic Reviews which is contained in the Cochrane Library. REVIEWS 400 350 300 250 200 150 100 50 COCHRANE NEONATAL: Published Reviews 0 2011 2013 2015 COCHRANE NEONATAL What has Cochrane Neonatal done for me lately? Or more importantly What has it done for babies? SOMETIMES COCHRANE REVIEWS CHANGE THE WAY WE PRACTICE AND SAVE BABIES LIVES! 3
CORTICOSTEROIDS FOR PRETERM BIRTH PROPHYLACTIC CORTICOSTEROIDS PRIOR TO PRETERM BIRTH EFFECT ON NEONATAL DEATH Since 1972, - there are multiple randomized controlled trials (N=18) - involving a large number of infants (3735 infants) but Antenatal corticosteroids were not utilized in the vast majority of patients until relative risk 0.63 (95% CI 0.51 to 0.77) PROPHYLACTIC CORTICOSTEROIDS PRIOR TO PRETERM BIRTH OVERVIEW OF 18 RANDOMIZED CONTROLLED TRIALS PROPHYLACTIC CORTICOSTEROIDS PRIOR TO PRETERM BIRTH OVERVIEW OF 15 RANDOMIZED CONTROLLED TRIALS Outcome (# of trials) Relative Risk Decreased Risk Increased ( 95% CI ) Outcome (# of trials) Relative Risk Decreased Risk Increased ( 95% CI ) RDS (14) 0.64 (0.56, 0.72) Periventricular hemorrhage (4) 0.57 (0.41, 0.78) Necrotizing enterocolitis (4) 0.60 (0.33, 1.09) Bronchopulmonary dysplasia (3) 1.38 (0.90, 2.11) Stillbirth (12) 0.84 (0.59, 1.21) Fetal/neonatal infection (15) 0.84 (0.60, 1.17) Maternal infection (11) 1.26 (0.99, 1.60) Neurological abnormality (3) 0.65 (0.39, 1.08) Neonatal death (13) 0.63 (0.51, 0.77) Crowley (1992) Relative Risk (95% CI) Crowley (1992) Relative Risk (95% CI) CORTICOSTEROIDS FOR PRETERM BIRTH Antenatal corticosteroid therapy is indicated for women at risk of premature delivery with few exceptions and will result in a substantial decrease in neonatal morbidity and mortality, as well as substantial savings in health care costs ANTENATAL CORTICOSTEROIDS 8 7 6 5 4 3 1 VERMONT OXFORD NETWORK ANNUAL REPORTS 1991- NIH Conference 1991 1992 1993 1994 1996 1998 2000 2002 2004 4
We re so proud of this, we made it part of our logo SOMETIMES COCHRANE REVIEWS TELL US WHAT WE ALREADY KNOW! www.cochrane.org SURFACTANT THERAPY EFFECT ON PNEUMOTHORAX SURFACTANT THERAPY EFFECT ON NEONATAL MORTALITY TYPES OF STUDIES (N) Risk Difference Decreased Risk Increased ( 95% CI ) TYPES OF STUDIES (N) Risk Difference Decreased Risk Increased ( 95% CI ) PROPHYLACTIC SURFACTANT PROPHYLACTIC SURFACTANT SYNTHETIC SURFACTANT (6) -0.05 (-0.09, -0.02) SYNTHETIC SURFACTANT (7) -0.07 (-0.11,-0.03) NATURAL SURFACTANT (8) -0.15 (-0, -0.11 ) NATURAL SURFACTANT (8) -0.07 (-0.12, -0.03 ) RESCUE SURFACTANT RESCUE SURFACTANT SYNTHETIC SURFACTANT (5) -0.09 (-0.12, -0.06) SYNTHETIC SURFACTANT (5) -0.05 (-0.07, -0.02) NATURAL SURFACTANT (12) -0.17 (-1, -0.13) NATURAL SURFACTANT (12) -0.09 (-0.13, -0.05) Soll Relative Risk (95% CI) Soll Relative Risk (95% CI) EXOGENOUS SURFACTANT TREATMENT VERMONT OXFORD NETWORK ANNUAL REPORTS 1991-2010 INTRODUCTION OF ANTENATAL STEROIDS AND POSTNATAL SURFACTANT TREATMENT EFFECT ON MORTALITY IN ELBW INFANTS 8 7 6 5 4 3 1 1991 FDA APPROVAL 1993 % ELBW INFANTS 9 8 7 6 5 4 3 1 1991 1992 1993 1994 1996 ANTENATAL STEROIDS SURFACTANT THERAPY MORTALTY 5
DELIVERY ROOM vs. TREATMENT SURFACTANT EFFECT ON NEONATAL MORTALITY SOMETIMES COCHRANE REVIEWS REFINE HOW WE PRACTICE! STUDY Kendig 1991 Dunn 1991 Egberts 1993 Kattwinkel 1993 Walti Bevilacqua 1996 Bevilacqua TYPICAL ESTIMATE Soll and Morley Decreased Risk Increased Relative Risk and 95% CI PROPHYLACTIC SURFACTANT AND STEROIDS EFFECT ON MORTALITY DUE TO RDS 70 MORTALITY DUE TO RDS (%) 60 50 40 30 20 10 0 SURF/STEROID SURF/NO STEROID NO SURF/STEROID NEITHER PROPHYLACTIC SURFACTANT vs. SELECTIVE TREATMENT OF RDS NEONATAL MORTALITY PROPHYLACTIC SURFACTANT vs. SELECTIVE TREATMENT OF RDS DEATH OR BPD 6
DR PRACTICES IN VLBW INFANTS % CASES 7 6 5 4 3 1 2000 2002 2004 2006 2008 SOMETIMES COCHRANE REVIEWS STOP US FROM DOING THINGS THAT MIGHT INJURE OUR BABIES! DR ETT DR SURFACTANT ROLE OF INFLAMMATION CHORIOAMNIONITIS AND BRONCHOPULMONARY DYSPLASIA POSTNATAL STEROID THERAPY: MECHANISM OF ACTION % CASES 9 8 7 6 5 4 3 1 BRONCHOPULMONARY DYSPLASIA ABSENT PRESENT stabilize cellular or lysosomal membranes decrease inflammatory response decrease pulmonary edema YOON AND COWORKERS. A SYSTEMIC FETAL INFLAMMATORY RESPONSE AND THE DEVELOPMENT OF BRONCHOPULMONARY DYSPLASIA. AM J OBSTET GYNECOL ;181:773-9 POSTNATAL STEROID THERAPY: POTENTIAL RISKS POSTNATAL STEROID THERAPY: SYSTEMATIC OVERVIEW hypertension hyperglycemia infection cardiomyopathy gi bleeding/perforation decreased somatic growth decreased brain growth neurodevelopmental problems Early Steroid Treatment: before or at 7 Days studies 32 enrolled infants 4395 Late Steroid Treatment: after 7 Days studies 21 enrolled infants 1424 Doyle L, Cheong JL, Ehrenkranz RA and Halliday HL, Cochrane Library 2017 7
EARLY ( 7 DAYS) POSTNATAL STEROID THERAPY EARLY ( 7 DAYS) POSTNATAL STEROID THERAPY META-ANALYSIS OF 32 RANDOMIZED CONTROLLED TRAILS Outcome (N Studies) Risk Difference ( 95% CI ) CLD @ 28 DAYS (17) -0.07 (-0.10,-0.03) CLD @ 36 WEEKS (24) -0.07 (-0.09, -0.04) DEATH/CLD @ 36 WKS (25) -0.06 (-0.09, -0.03) MORTALITY (30) -0.01 (-0.03, 0.01) Decreased Risk Increased EFFECT ON COMPLICATIONS OF PREMATURITY OUTCOME (N STUDIES) PULMONARY AIR LEAK (16) PATENT DUCTUS ARTERIOSUS (24) INFECTION (25) HYPERTENSION (11) GI HEMORRHAGE (12) SEVERE IVH (26) SEVERE ROP (14) Decreased Risk Increased Doyle 2017 Relative Risk and 95% CI Doyle 2017 Relative Risk and 95% CI LATE (> 7 DAYS) POSTNATAL STEROID THERAPY EARLY ( 7 DAYS) POSTNATAL STEROID THERAPY META-ANALYSIS OF 21 RANDOMIZED CONTROLLED TRAILS Outcome (N Studies) Risk Difference ( 95% CI ) CLD @ 28 DAYS (6) -0.11 (-0.17, -0.05) CLD @ 36 WEEKS (11) -0.15 (-2, -0.07) DEATH/CLD @ 36 WKS (11) -0.18 (-5, -0.11) MORTALITY (19) -0.03 (-0.07, 0.02) Decreased Risk Increased PVL (15) NEURODEVELOPMENTAL OUTCOME IN SURVIVORS OUTCOME (N Studies) BAYLEY MDI < 2SD (3) 0.01 (-0.06, 0.06) BAYLEY PDI < 2SD (3) 0.02 (-0.02, 0.07) ABNORMAL NEURO EXAM (5) DEVELOPMENTAL DELAY (1) CEREBRAL PALSY (13) 0.02 (-0.00, 0.05) Risk Difference Decreased Risk Increased ( 95% CI ) 0.00 (-0.01, 0.02) 0.10 (0.05, 0.15) 0.14 (0.03, 4) Doyle 2017 Relative Risk and 95% CI MOD/SEVERE IMPAIRMENT (7) 0.01 (-0.02, 0.05) Doyle 2017 Relative Risk and 95% CI LATE (> 7 DAYS) POSTNATAL STEROID THERAPY NEURODEVELOPMENTAL OUTCOME IN SURVIVORS Outcome (N) BAYLEY MDI < 2SD (7) BAYLEY PDI < 2SD (1) ABNORMAL NEURO EXAM (4) CEREBRAL PALSY (15) Risk Difference (95%CI) -0.03 (-0.10, 0.05) -0.04 (-0.17, 0.09) 0.15 (-0.00, 0.30) -0.02 (-0.08, 0.03) MOD/SEVERE IMPAIRMENT (9) 0.03 (-0.03, 0.08) Decreased Risk Increased POSTNATAL CORTICOSTEROIDS TO TREAT OR PREVENT CHRONIC LUNG DISEASE IN PRETERM INFANTS RECOMMENDATIONS FROM THE COMMITTEE ON THE FETUS AND NEWBORN 2002 On the basis of limited short-term benefits, the absence of long-term benefits, and the number of serious short-term and long-term complications, the routine use of systemic dexamethasone for the prevention or treatment of chronic lung disease in infants with very low birth weight is not recommended. Doyle 2017 Relative Risk and 95% CI 8
POSTNATAL CORTICOSTEROIDS TO TREAT OR PREVENT CHRONIC LUNG DISEASE IN PRETERM INFANTS RECOMMENDATIONS FROM THE COMMITTEE ON THE FETUS AND NEWBORN 2002 Outside the context of a randomized controlled trial, the use of corticosteroids should be limited to exceptional clinical circumstances (e.g., an infant on maximal ventilatory and oxygen support). In those circumstances, parents should be fully informed about the known short- and long-term risks and agree to treat. 3 1 1991 Postnatal Corticosteroid Use in VLBW Infants VERMONT OXFORD NETWORK ANNUAL REPORTS 1991-2014 1993 Cochrane Review AAP Statement 2011 2013 Postnatal Steroids Risk Difference (%) for Death or CP among all participants vs. rate of CLD (%) in the control group 5 4 Doyle, L. W. et al. Pediatrics ;115:655-661 3 1 1990 1991 1992 1993 1994 1996 1998 2000 2002 2004 2006 2008 2010 2011 2012 2013 CLD Cerebral palsy 9
Intraventricular Hemorrhage SOMETIMES COCHRANE REVIEWS PROVIDE RESULTS THAT MAY BE CONFUSING! VERMONT OXFORD NETWORK ANNUAL REPORTS 1991-2015 6 5 4 3 1 1991 1993 2011 2013 2015 Any Intraventricular Hemorrhage Severe Intraventricular Hemorrhage Prophylactic Indomethacin Meta-analysis of 19 trials EFFECT ON PATENT DUCTUS ARTERIOSUS (PDA) Risk Difference Decreased Risk Increased Outcome ( 95% CI ) Prophylactic Indomethacin Meta-analysis of 19 trials EFFECT ON CENTRAL NERVOUS SYSTEM INJURY Risk Difference Decreased Risk Increased Outcome ( 95% CI ) PATENT DUCTUS ARTERIOSUS (7) -7 (-0.32, -1) SYMPTOMATIC PDA (14) -4 (-8, -1) PDA LIGATION (8) -0.05 (-0.08, -0.03) INTRAVENTRICULAR HEMORRHAGE (14) -0.04 (-0.08, -0.01) SEVERE IVH (14) -0.05 (-0.07, -0.02) PROGRESSIVE IVH (2) -0.08 (-9, 0.13) PERIVENTRICULAR LEUKOMALACIA (5) -0.05 (-0.08, -0.01) WHITE MATTER INJURY (1) -0.04 (-0.07, 0.00) FOWLIE 2010: THE COCHRANE LIBRARY Relative Risk and 95% CI FOWLIE 2010: THE COCHRANE LIBRARY Relative Risk and 95% CI Long-Term Effects of Indomethacin Prophylaxis in ELBW Infants Schmidt B and colleagues. N Engl J Med ; 344:1966-1972 Original Article Long-Term Effects of Indomethacin Prophylaxis in Extremely-Low-Birth- Weight Infants Barbara Schmidt, M.D., Peter Davis, M.D., Diane Moddemann, M.D., Arne Ohlsson, M.D., Robin S. Roberts, M.Sc., Saroj Saigal, M.D., Alfonso Solimano, M.D., Michael Vincer, M.D., and Linda L. Wright, M.D., for the Trial of Indomethacin Prophylaxis in Preterms Investigators* N Engl J Med ; 344:1966-1972June 28, DOI: 10.1056/NEJM06283442602 10
Long-Term Effects of Indomethacin Prophylaxis in ELBW Infants Schmidt B and colleagues. N Engl J Med ; 344:1966-1972 Long-Term Effects of Indomethacin Prophylaxis in ELBW Infants Schmidt B and colleagues. N Engl J Med ; 344:1966-1972 Schmidt and colleagues randomly assigned 1202 extremely low birth weight infants to receive either indomethacin (0.1 mg/kg) or placebo intravenously once daily for three days. The primary outcome was a composite of death, cerebral palsy, cognitive delay, deafness, and blindness at a corrected age of 18 months. Outcome Composite Death or impairment Components Indomethacin 47% Control 46% Adjusted OR (95% CI) 1.1 (0.8 to 1.4) Secondary short-term outcomes were patent ductus arteriosus, pulmonary hemorrhage, chronic lung disease, ultrasonographic evidence of intracranial abnormalities, necrotizing enterocolitis, and retinopathy. Secondary long-term outcomes were hydrocephalus necessitating the placement of a shunt, seizure disorder, and microcephaly within the same time frame. Death CP Cognitive delay Hearing loss Blindness 21% 12% 27% 2% 2% 19% 12% 26% 2% 1% 1.2 (0.9 to 1.6) 1.1 (0.7 to 1.6) 1.0 (0.8 to 1.4) 1.0 (0.4 to 2.5) 1.3 (0.5 to 3.6) Prophylactic Indomethacin Meta-analysis of 19 trials STATUS AT LATEST FOLLOW UP Hierarchy of outcomes according to importance to patients to assess effect of prophylactic indomethacin Mortality Outcome Risk Difference Decreased Risk Increased ( 95% CI ) Neurodevelopmental outcome Severe IVH MORTALITY AT FOLLOW UP (18) -0.01 (-0.04, 0.02) PDA ligation CEREBRAL PALSY (4) 0.00 (-0.03, 0.04) SEVERE ND IMPAIRMENT (3) -0.01 (-0.05, 0.04) PDA murmur FOWLIE 2010: THE COCHRANE LIBRARY Relative Risk and 95% CI Prophylactic Indomethacin: Glass half full or half empty? Indomethacin VERMONT OXFORD NETWORK ANNUAL REPORTS 1991-2015 8 PREVENTS: SYMPTOMATIC PDA SEVERE IVH DOES NOT ALTER NEURODEVELOPMENTAL OUTCOME 7 6 5 4 3 1 1991 1993 2011 2013 2015 11
SOMETIMES WE IGNORE THE FINDINGS FROM RANDOMIZED CONTROLLED TRIALS AND THE REVIEWS OF THESE TRIALS! ELECTIVE HIGH FREQUENCY OSCILLATORY VENTILATION META-ANALYSIS OF 19 RANDOMIZED CONTROLLED TRIALS OUTCOME (STUDIES) Risk Difference Decreased Risk Increased ( 95% CI ) PULMONARY AIRLEAK (13) 0.04 (0.01, 0.07) IVH (12) 0.02 (-0.01, 0.05) SEVERE IVH (18) 0.01 (-0.01, 0.04) PVL (17) 0.00 (-0.01, 0.02) SEVERE RETINOPATHY (12) -0.04 (-0.07, -0.01) CHRONIC LUNG DISEASE (17) -0.05 (-0.08, -0.02) High Frequency Ventilation VERMONT OXFORD NETWORK ANNUAL REPORTS 1991-2014 3 1 DEATH (17) -0.01 (-0.03, 0.02) CLD/DEATH @ 36 WKS PMA (17) -0.05 (-0.08, -0.01) COOLS 2015 Relative Risk and 95% CI 1991 1993 2011 2013 CHRONIC LUNG DISEASE IN VLBW INFANTS VERMONT OXFORD NETWORK ANNUAL REPORTS 1994-2010 MORTALITY IN VLBW INFANTS VERMONT OXFORD NETWORK ANNUAL REPORTS 1991-2010 4 3 1 1994 1996 1998 2000 2002 2004 2006 2008 2010 15% 1 5% 1991 1993 12
NITRIC OXIDE FOR RESPIRATORY FAILURE IN PRETERM INFANTS EFFECT ON DEATH OR BPD AT 36 WEEKS PMA NIH Consensus Development Conference Statement: Inhaled Nitric- Oxide Therapy for Premature Infants Taken as a whole, the available evidence does not support use of ino in early-routine, early-rescue, or later-rescue regimens in the care of premature infants of <34 weeks' gestation who require respiratory support. There are rare clinical situations, including pulmonary hypertension or hypoplasia, that have been inadequately studied in which ino may have benefit in infants of <34 weeks' gestation. In such situations, clinicians should communicate with families regarding the current evidence on its risks and benefits as well as remaining uncertainties. Inhaled Nitric Oxide in VLBW Infants Vermont Oxford Network Annual Reports 2000-2012 Range 3 rd quartile 1 st quartile SOMETIMES THE COCHRANE REVIEW TELLS 15% US THAT WE SHOULD BE READY TO CONSIDER 1 CHANGE 5% (AND NEW PRACTICES) 2008 2010 2011 2012 2013 COOLING FOR INFANTS WITH HYPOXIC ISCHEMIC ENCEPHALOPATHY HYPOTHERMIA FOR HYPOXIC ISCHEMIC ENCEPHALOPATHY WHOLE BODY COOLING AND SELECTIVE HEAD COOLING STUDY Risk Difference Decreased Risk Increased (95%CI) SELECTIVE HEAD COOLING DEATH -0.05 (-0.14, 0.04) MAJOR DISABILITY -0.09 (-4, 0.05) DEATH OR MAJOR DISABILITY -0.09 (-1, 0.03) WHOLE BODY COOLING DEATH -0.10 (-0.16, -0.04) MAJOR DISABILITY -0.18 (-9, -0.09) DEATH OR MAJOR DISABILITY -0.16 (-3, -0.09) Updated by Berg 2012 Relative Risk and 95% CI 13
HYPOTHERMIA FOR THE TREATMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHY COOLING IN HYPOXIC ISCHEMIC ENCEPHALOPATHY ILCOR recommendations Intensive care nurseries should now consider adopting one of the validated protocols for the selection of term infants with HIE, be appropriately equipped and train staff to offer hypothermia according to the protocol of the currently published large hypothermia trials Because HIE is a relatively uncommon condition, it would be highly desirable where possible to centralize this treatment to larger intensive care units. What are we supposed to do? With the data presently available, there is no longer any reasonable justification to deny this apparently efficacious treatment for those who most urgently need it. Hoehn and coworkers. Resuscitation 2008 DIFFICULTY OF TRANSLATING EVIDENCE TO PRACTICE Efficacy: Mild hypothermia is a promising therapy in a highly selected population of infants with moderate to severe hypoxic ischemic encephalopathy when treated before 6 hours of age DIFFICULTY OF TRANSLATING EVIDENCE TO PRACTICE Effectiveness and Efficiency: Does it work in the most affected infants? Does it provide a benefit to less severely affected infants? Does it work outside the restricted time window predicted by animal models and tested in clinical trials? Does selective or whole body hypothermia work better? What is the relationship of hypothermia to other therapeutic interventions? ENCEPHALOPATHY REGISTRY: Hypothermic Therapy 2006 to 2011 PROBLEMS WITH META-ANALYSIS 99 participating centers 2457 infants treated with hypothermia 726 (3) did not meet criteria from RCTs 4 with mild encephalopathy 6 treated after 6 hours 17% of all infants < 36 weeks gestation Only fair agreement between large clinical trials and meta-analyses LeLorier Whole Body 74% Selective Head 17% Both 9% Pfister. PAS. 2013 14
META-ANALYSIS OF MULTIPLE SMALL STUDIES COMPARED TO SINGLE LARGE STUDY META-ANALYSIS ASPIRIN FOR PREVENTION OF PRE-ECLAMPSIA CHARACTERISTIC Odds Ratio Decreased Risk Increased (95% CI) META-ANALYSIS 0.30 (0, 0.42) SINGLE LARGE RCT 0.82 (0.72, 1.05) Methodological flaws in meta-analyses Publication bias The tendency for investigators to preferentially submit studies with positive results, and the tendency for editors to choose positive studies for publication Odds Ratio and 95% CI Heterogeneity Concerning variation in the direction or the degrees of results between individual studies PROBLEMS WITH COCHRANE REVIEWS AND META-ANALYSIS RCTs Too many reviews that end with the conclusion that more trials are needed. Cochrane Reviews You cannot make a silk purse from a sow s ear TRIALS BASED (at least in part) on RESULTS OF META-ANALYSIS Prophylactic Indomethacin Vitamin A Emollient Ointments DART Trial Inositol Caffeine Search: Neonate Limit: all infants; randomized controlled trial 7059 RCT identified Cochrane Neonatal 1355 RCTs included 15
COCHRANE NEONATAL SYSTEMATIC REVIEWS ARE USEFUL In guiding evidence-based practice To formulate research questions To create a context in which to view new evidence So what is the fate of Cochrane Neonatal? So what is the fate of Cochrane Neonatal? Bridging funds: University of Vermont Cochrane Central Possible future sponsorship: Questions Vermont Oxford Network For CME Credits use the following link: https://www.surveymonkey.com/r/vs9ck2z For Nursing Contact Hours use the following link: https://www.surveymonkey.com/r/fjpdjrz Future webinars! Prevention and Treatment of Retinopathy of Prematurity 16